Full-Time

Field Medical Director/ Sr. Field Medical Director

Posted on 4/15/2025

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Compensation Overview

$190k - $245k/yr

Senior

No H1B Sponsorship

United States

All candidates must reside in the United States.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • Candidates with a PharmD, Ph.D., MD, Genetic Counseling, as well as other advanced healthcare degrees or relevant experience, will be considered
  • 3+ years of medical affairs or field medical experience with a verifiable record of high performance is preferred, or at least 2 years of other relevant clinical or healthcare experience will be considered
  • Prior experience in rare diseases and/or skeletal dysplasia is preferred
  • Excellent interpersonal communication and presentation skills (including networking)
  • Able to participate in a scientific dialogue with KOLs and researchers
  • Excellent teaching skills and ability to present and discuss scientific material clearly and concisely
  • Proven ability to create and sustain relationships with industry leaders
  • Skilled in clinical research and an understanding of the process of pharmaceutical product development and approval
  • Demonstrated ability to organize, prioritize, and work effectively with minimal supervision in a constantly changing environment
  • Travel 60-70% of the time depending on territory size; overnight and weekend work will be involved with some variation based upon the demands of the business imperatives
  • Occasional international travel may be required
  • All candidates must reside in the United States
Responsibilities
  • Collaborate with National Head, Field Medical Affairs in the development and execution of scientific plans within their territory to meet company-defined goals within corporate and regulatory guidelines for products both marketed and in development
  • Lead the execution of Medical Affairs strategic plans in territory
  • Maintain clinical/technical expertise in specific therapeutic areas; review scientific journals, attend scientific and key technical meetings in territory and share learnings with key stakeholders
  • Serve as resource to the commercial team on scientific/market intelligence
  • Proactively provide feedback on emerging clinical/competitive trends
  • Identify and build advocacy with key investigators and key accounts to facilitate mutually beneficial research on infigratinib
  • Develop field-based relationships with KOLs, HCPs, Clinics, etc. in support of strategic plans and may contribute to HCP strategies for multiple brands
  • Develops, maintains and leverages strategic relationships with professional societies consistent with Medical Affairs goals
  • Develops, maintains and leverages strategic relationships with scientific board of patient advocacy groups consistent with medical affairs goals
  • Demonstrates advanced HCP development and relationship skills across differing HCP segments
  • Takes the lead in identification of new HCP segments and opportunities for Medical Affairs engagement
  • Act as primary source of scientific product knowledge in territory (question escalation from HCPs, Clinics, etc.)
  • Deliver high quality scientific presentations on infigratinib to physicians and other key external customers
  • Provide medical support for commercial efforts in support of infigratinib such as representing BridgeBio/QED and infigratinib at Medical Affairs booths during scientific symposia
  • Assist in the management of territory KOLs / Investigators (IRs) involved in publications in collaboration with Medical Affairs stakeholders, as needed
  • Recognize and share any key information received in field meetings that is critical to Medical strategy such as adverse events, safety issues, or other field intelligence
  • Gather competitive intelligence and clinical insights from the field and provide to BridgeBio/QED competitive intelligence function and Medical Director indication lead
  • Visit potential research sites to determine the site’s ability to conduct and accrue to clinical research studies and registries (i.e. patient volume, research experience, methodologies, competing studies, etc.)
  • Implementation and coordination of independent research (investigator sponsored trials – ISTs) activities intended to support the clinical and scientific strategy for infigratinib
  • Able to gain team and stakeholder alignment on research implications and facilitate cross-functional discussions on recommended actions
  • Liaise with the Study Management and/or Clinical function by forwarding potential investigators for other BridgeBio/QED products in development
  • Skilled in interpretation and application of clinical data
  • Through peer education, enables other MSLs and stakeholders to build their data analysis and synthesis skills, and understand the implications of research results for the business
  • Serves as a lead for clinical trial/research activities
  • Support BridgeBio/QED sponsored clinical studies (Site Initiation Visit (SIV), Phase III trials) and registry (marketed) studies at sites in the territory by providing training, responding to inquiries, sharing feedback and new information, as appropriate
  • For an assigned product, collaborate with key stakeholders in the development of field medical product strategies in support of a Regional Medical Plan
  • Develop and maintain thorough understanding of product and disease areas
  • Demonstrate thorough understanding of BridgeBio/QED clinical and commercial priorities for product
  • Collaborate with MDs and Medical Information on the development and maintenance of the infigratinib medical narrative decks which are used as a basis in responding to any unsolicited inquiries to MDs, FMDs and Medical Information
  • Assist with the creation, updating, and maintenance of field facing materials for external/internal education initiatives
  • Helps to assess knowledge/skill gaps of others and provide developmental support as needed
  • Provides guidance and coaching to others in developing and applying scientific and HCP insights
  • Serves as an internal and external authority on the scientific and medical aspects of the business and industry
  • Contributes to scientific literature and participates in scientific dialogue with external medical experts, and internal US and global medical teams
  • Handle product scientific question escalation from the field or territory leads
  • Conduct product specific scientific training and field meetings with company new hires, colleagues in Commercial and external stakeholders
  • Assist in the training of new commercial recruits by presenting the scientific disease and product related data and present at sales conferences, regional meetings, etc. to develop high level of medical knowledge within sales force
  • Deep knowledge of current healthcare environment and implications to MEDICAL AFFAIRS
  • Translates trends in managed markets space into possible strategies for MEDICAL AFFAIRS
  • Applies knowledge of the current US Healthcare System to MEDICAL AFFAIRS
  • Demonstrates broad knowledge and understanding of all aspects of the US Healthcare System and serves as a resource for US Medical Affairs
  • Serves as the scientific resource the NAM team utilizes for deep scientific discussions with payers
  • Provide field feedback for Managed Market objection handler / slide deck development
Desired Qualifications
  • Prior experience in rare diseases and/or skeletal dysplasia is preferred
  • 3+ years of medical affairs or field medical experience with a verifiable record of high performance is preferred, or at least 2 years of other relevant clinical or healthcare experience will be considered

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific diseases while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create therapies that address the genetic roots of diseases, potentially leading to significant improvements in patient outcomes. With over 15 drug programs targeting 20 different genetic diseases, BridgeBio aims to expedite the drug development process and bring new treatments to market more quickly. Their culture emphasizes independent thinking and transparency, promoting rapid, data-driven decision-making.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent approval of Beyonttra in Japan enhances BridgeBio's market presence.
  • Advancements in CRISPR and gene-editing expand therapeutic capabilities.
  • Strategic partnerships with academic institutions foster innovation and research opportunities.

What critics are saying

  • Increased competition from Alnylam Pharmaceuticals' Amvuttra in ATTR amyloidosis market.
  • Potential slow market penetration of Beyonttra in Japan affecting revenue.
  • Refinancing $500 million debt could increase financial risk if revenue growth lags.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focuses on genetic diseases with well-understood genetic causes for targeted therapies.
  • Leverages genome sequencing and molecular biology for innovative treatment solutions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

↓ -2%

1 year growth

↑ 0%

2 year growth

↓ -1%
Bitcoin Ethereum News
Jun 20th, 2025
Parataxis Korea's $18.5M BTC Strategy

Parataxis Holdings is launching a BTC treasury company in South Korea through a reverse merger with Bridge Biotherapeutics, valued at â‚©25M ($18.5M). The new entity, Parataxis Korea, aims to emulate the BTC strategies of Strategy in the US and Metaplanet in Japan. Bridge Biotherapeutics, previously distressed, saw its stock rise after the BTC strategy shift. Parataxis Capital, affiliated with Parataxis Holdings, is a Tier-4 investment fund with a focus on crypto projects.

Stock Titan
May 12th, 2025
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BridgeBio Pharma (Nasdaq: BBIO) announced its upcoming presentations at the Heart Failure 2025 conference in Belgrade, Serbia from May 17-20, 2025.

TradingView
May 12th, 2025
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BridgeBio to present clinical outcomes, Quality of Life measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM study at the Annual Congress of the Heart Failure Association of the ESC.

BioSpace
Mar 29th, 2025
Beyonttra(Tm) (Acoramidis), The First Near-Complete Ttr Stabilizer (>=90%), Approved In Japan To Treat Attr-Cm

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30BridgeBio will receive a $30 million milestone payment from Alexion, AstraZeneca Rare Disease, with royalties in the low double digits on net sales of Beyonttra in JapanPALO ALTO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Japanese Ministry of Health, Labour and Welfare has approved acoramidis, under the brand name Beyonttra, for the treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer. Relative increases in serum TTR concentrations resulting from greater TTR stability have been associated with reduced risk of all-cause and cardiovascular mortality in the general population in recent literature.1 ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. Alexion, AstraZeneca Rare Disease will be responsible for all commercial activity for Beyonttra in Japan.“There is significant need for new treatment options for ATTR-CM, a progressive, fatal disease, worldwide

BioSpace
Mar 25th, 2025
Bridgebio To Present Cardiovascular Outcomes Data In Patients With Variant And Wild-Type Transthyretin Amyloid Cardiomyopathy (Attr-Cm) From The Attribute-Cm Study At The Acc Annual Scientific Sessions

PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in Chicago, Illinois on March 29-31, 2025. Additionally, BridgeBio was selected to share five poster presentations and two moderated posters on ATTR-CM.Flatboard Poster Presentations:Acoramidis Improves Serum TTR Levels in Patients with Wild-type or Variant Transthyretin Amyloid CardiomyopathyPresenter: Margot Davis, M.D. of Vancouver General Hospital, CADate: Monday, March 31 at 9:00 am CT/10:00 am ETAcoramidis Improves NYHA Class at Month 30 Versus Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM StudyPresenter: Kevin Alexander, M.D. of Stanford University School of Medicine, USADate: Sunday, March 30 at 1:30 pm CT/2:30 pm ETIn Participants Treated with Acoramidis, Addition of Concomitant Tafamidis Did Not Further Increase Serum TTR LevelsPresenter: Mathew Maurer, M.D. of Columbia University Irving Medical Center, USADate: Monday, March 31 at 9:00 am CT/10:00 am ETRobustness of Primary Endpoint Efficacy Results with Acoramidis in ATTR-CM in the ATTRibute-CM Study: Pre-specified NT-proBNP Sensitivity AnalysesPresenter: Jan Griffin, M.D

INACTIVE